Member Exclusive INTERVIEW

#TalkingRegMed 7: Cell therapy and big pharma with Sven Kili, GSK

​In this exclusive video, Sven Kili, ‎VP and Head of Cell & Gene Therapy Development, GSK, explains why rare diseases are so amenable to treatment with cell therapies.

Go to the profile of RegMedNet
May 09, 2018

Please sign in or register for FREE


Go to the profile of James L. Sherley, M.D., Ph.D.

Cell therapy production, tissue stem cell manufacturing in particular, is primarily limited by biology, not cost.

James Sherley at Asymmetrex